Nvidia's Venture Arm Raises Stake in AI Drug Discoverer Genesis Therapeutics

Full Article
Nvidia's Venture Arm Raises Stake in AI Drug Discoverer Genesis Therapeutics

Genesis Therapeutics, an AI-driven drug discovery company, has received additional investment from NVentures, Nvidia's venture capital arm. This funding aims to enhance Genesis's AI platform, Genesis Exploration of Molecular Space (GEMS), which focuses on optimizing molecules for complex drug targets. The collaboration leverages Nvidia's expertise in AI hardware and software to improve computational efficiency in drug design.

Founded in 2019, Genesis has rapidly grown, raising over $300 million, including a significant $200 million Series B round in 2023. The partnership with Nvidia is expected to accelerate the development of innovative AI techniques for drug discovery, particularly in oncology and immunology. Genesis's GEMS platform aims to tackle challenging drug targets, showcasing the synergy between Nvidia's technology and Genesis's molecular AI expertise.

• Genesis Therapeutics enhances AI drug discovery with Nvidia's investment.

• GEMS platform aims to optimize drug candidates for complex targets.

Key AI Terms Mentioned in this Article

AI Platform

GEMS is an AI platform designed to generate and optimize molecules for drug discovery.

Neural Networks

Equivariant neural networks are optimized for handling 3D geometric data in molecular structures.

Molecular AI

Genesis has pioneered molecular AI, focusing on algorithms suited for drug discovery tasks.

Companies Mentioned in this Article

Nvidia

Nvidia is a leader in AI hardware and software, enhancing drug discovery through its collaboration with Genesis.

Genesis Therapeutics

Genesis Therapeutics specializes in AI-driven drug discovery, utilizing its GEMS platform to optimize drug candidates.

Get Email Alerts for AI News

By creating an email alert, you agree to AIleap's Terms of Service and Privacy Policy. You can pause or unsubscribe from email alerts at any time.

Latest Articles

Alphabet's AI drug discovery platform Isomorphic Labs raises $600M from Thrive
TechCrunch 6month

Isomorphic Labs, the AI drug discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital for the first time. The $600

AI In Education - Up-level Your Teaching With AI By Cloning Yourself
Forbes 6month

How to level up your teaching with AI. Discover how to use clones and GPTs in your classroom—personalized AI teaching is the future.

Trump's Third Term - How AI Can Help To Overthrow The US Government
Forbes 6month

Trump's Third Term? AI already knows how this can be done. A study shows how OpenAI, Grok, DeepSeek & Google outline ways to dismantle U.S. democracy.

Sam Altman Says OpenAI Will Release an 'Open Weight' AI Model This Summer
Wired 6month

Sam Altman today revealed that OpenAI will release an open weight artificial intelligence model in the coming months. "We are excited to release a powerful new open-weight language model with reasoning in the coming months," Altman wrote on X.

Popular Topics